Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class II · Moderate risk Terminated Initiated Mar 3, 2016 (11 years ago)

Zoledronic Acid Injection

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

Lack of Assurance of Sterility; defective seals where the metal silver ring was not attached tightly to the vial

Cause type: Sterility / contamination

A product that must be sterile could not be assured sterile, or was contaminated. A top reason for injectables, eye drops and IV products - loss of sterility assurance can lead to serious infections. All sterility / contamination recalls.

What was recalled

Zoledronic Acid Injection, 5 mg/100 mL (0.05 mg/mL), 100 mL Single Use Bottle, Rx Only, Mfd. By: Gland Pharma Limited D.P. Pally - 500 043 INDIA NDC 55111-688-52

Affected NDC 55111-0688-52

Compare with the code on your package — it is the most precise check available.

Drug: Zoledronic

Product details

From the FDA NDC directory, for the product code this recall names. Compare with the label on your package.

ProductStrengthForm & routeLabelerType
Zoledronic Acid
NDC 55111-0688
5 mg/100mL Injection, Solution
Intravenous
Dr.Reddy's Laboratories Ltd Rx
Recalling firm
Dr. Reddy's Laboratories, Inc.
NDC code
55111-688-52
Origin
NJ, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-0784-2016 · FDA notice

Check, then ask. Class II means harm is possible but usually temporary or reversible. Find the lot number on your package; if it matches, ask your pharmacist about a replacement. Do not simply stop a prescribed medication on your own - the gap can be riskier than the recall. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other Zoledronic recalls

See all
Class III · Low risk

Zoledronic Acid Injection 5 mg/100 mL

Failed Impurities/Degradation Specifications: Out-of-specification results obtained for impurities during stability testing.

Terminated Impurity / degradation Breckenridge Pharmaceutical, Inc NDC 51991-064-98 D-1063-2020
Class II · Moderate risk

Zoledronic Acid active pharmaceutical ingredient packaged in…

Penicillin Cross Contamination: All lots of all products repackaged and distributed between 01/05/12 and 02/12/15 are being recalled because they were repackaged in a facility with penicillin products without adequate separation which could introduce the potential for cross contamination with penicillin.

Terminated Cross-contamination Attix Pharmaceuticals D-958-2015

Other recalls by Dr. Reddy's Laboratories, Inc.

All 2016 recalls
Class III · Low risk

Varenicline Tablets

Sub potent drug: during the 9-month stability test conducted, the assay value for the affected lot was below specification limit.

Ongoing Wrong potency / content Dr. Reddy's Laboratories, Inc. NDC 43598-908-56 D-0219-2026
Class II · Moderate risk

Omeprazole Delayed-release Capsules

Presence of foreign tablets/capsules: presence of foreign Divalproex Sodium Extended-Release 250mg tablet in a bottle of omeprazole capsules.

Ongoing Particulate / foreign matter Dr. Reddy's Laboratories, Inc. NDC 82009-022-10 D-0525-2025
Class I · High risk

Levetiracetam 0.75% in Sodium Chloride Injection 1

LABELING: LABEL MIX-UP: The infusion bag is incorrectly labeled as Levetiracetam in 0.82% Sodium Chloride Injection 500 mg/100 mL, while the aluminum overwrap packaging correctly identifies the product as Levetiracetam in 0.75% Sodium Chloride Injection 1,000 mg/100 mL.

Ongoing Labeling / mix-up Dr. Reddy's Laboratories, Inc. NDC 43598-636-52 D-0365-2025